Avis AI Thyroid Cancer Diagnosis Tech Wins Edison Award Silver

Medical artificial intelligence (AI) specialized company AVIBIS's thyroid cancer diagnosis pathology AI solution, 'PathoAiD®-Thyroid Dx,' received a silver award at the '2025 Edison Awards' in the United States, earning global recognition for its innovation and technological prowess. PathoAiD was developed to address uncertainties and misdiagnosis issues that can arise during the pathological diagnosis of thyroid nodules. This solution uses AI to directly analyze thyroid nodule tissue slide images, accurately differentiating between benign and malignant conditions. This contributes significantly to reducing unnecessary surgeries and the financial and physical burden on patients. Notably, PathoAiD offers cost savings of up to 80% compared to expensive molecular tests and dramatically shortens the analysis period, which previously took over four weeks in traditional diagnostic processes, to just a few minutes, maximizing patient convenience. This technical excellence and social value were simultaneously highly evaluated, leading to the Edison Award. The Edison Awards is a prestigious awards ceremony that honors the achievements of the world-renowned inventor Thomas Edison, comprehensively evaluating innovation, technological excellence, marketability, and social impact. AVIBIS also presented two research achievements related to PathoAiD's core AI technology at the 'USCAP 2025 (United States and Canadian Academy of Pathology 2025)' held in Boston, USA, last March. These presentations firmly demonstrated the clinical applicability of the solution, showing a high concordance between AI-generated heatmaps and the regions interpreted by actual pathology specialists. Lee Dae-hong, CEO of AVIBIS, stated, "This Edison Award is an important opportunity to prove the global competitiveness of AVIBIS's thyroid cancer diagnosis AI solution," adding, "We will continue to lead AI-based innovation in the field of precision medicine and do our best to actively promote the excellence of Korean medical technology to the global pathology community." AVIBIS is expected to lead the medical AI market by changing the paradigm of thyroid cancer diagnosis through PathoAiD.